Advanced colorectal cancer (CRC) is often accompanied by development of liver metastases (LMs) and skeletal muscle (SkM) wasting, i.e. cachexia. Despite plaguing the majority of CRC patients, cachexia remains unresolved. By using mice subcutaneously (C26) or intrasplenically injected with C26 tumor cells to mimic hepatic dissemination of cancer cells (mC26), here we aimed to further characterize functional, molecular and metabolic effects on SkM and examine whether LMs exacerbate CRC-induced cachexia. C26-derived LMs were associated with progressive loss of body weight, as well as with significant reductions in SkM size and strength, in line with reduced phosphorylation of markers of protein anabolism and enhanced protein catabolism. mC26 hosts showed prevalence of fibers with glycolytic metabolism and enhanced lipid accumulation, consistent with abnormalities of mitochondrial homeostasis and energy metabolism. In a comparison with mice bearing subcutaneous C26, cachexia appeared exacerbated in the mC26 hosts, as also supported by differentially expressed pathways within SkM. Overall, our model recapitulates the cachectic phenotype of metastatic CRC and reveals that formation of LMs resulting from CRC exacerbate cancer-induced SkM wasting by promoting differential gene expression signatures.
Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia

Joshua R. Huot1*, Leah J. Novinger2*, Fabrizio Pin3, Ashok Narasimhan1, Teresa A. Zimmers1,3,4,5, Thomas M. O’Connell2,3,4,5, Andrea Bonetto1,2,3,4,5

1Department of Surgery; 2Department of Otolaryngology-Head & Neck Surgery; 3Department of Anatomy, Cell Biology and Physiology; 4Simon Cancer Center; 5Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA.

Corresponding author:
Andrea Bonetto, PhD
Assistant Professor
Department of Surgery, Indiana University School of Medicine
980 W Walnut Street, R3-C522
Indianapolis, IN 46202
abonetto@iu.edu
Phone: 317-278-0302
Fax: 317-274-8046
*Authors contributed equally

Conflicts of interest: The authors have declared that no conflict of interest exists.
Abstract

Advanced colorectal cancer (CRC) is often accompanied by development of liver metastases (LMs) and skeletal muscle (SkM) wasting, i.e. cachexia. Despite plaguing the majority of CRC patients, cachexia remains unresolved. By using mice subcutaneously (C26) or intrasplenically injected with C26 tumor cells to mimic hepatic dissemination of cancer cells (mC26), here we aimed to further characterize functional, molecular and metabolic effects on SkM and examine whether LMs exacerbate CRC-induced cachexia. C26-derived LMs were associated with progressive loss of body weight, as well as with significant reductions in SkM size and strength, in line with reduced phosphorylation of markers of protein anabolism and enhanced protein catabolism. mC26 hosts showed prevalence of fibers with glycolytic metabolism and enhanced lipid accumulation, consistent with abnormalities of mitochondrial homeostasis and energy metabolism. In a comparison with mice bearing subcutaneous C26, cachexia appeared exacerbated in the mC26 hosts, as also supported by differentially expressed pathways within SkM. Overall, our model recapitulates the cachectic phenotype of metastatic CRC and reveals that formation of LMs resulting from CRC exacerbate cancer-induced SkM wasting by promoting differential gene expression signatures.

Key words: cachexia; colorectal cancer; liver metastases; skeletal muscle; C26 tumor; bone; metabolism
Introduction

By the end of 2020 about 148,000 new cases of colorectal cancer (CRC) are expected to be diagnosed in the United States, and over 53,000 people will ultimately die from the disease, thus representing the second leading cause of death among all cancers (1). Notably, in 70% of CRC cases the most serious impediment is the development of liver metastases (LMs), frequently accompanied by the onset of skeletal muscle wasting, i.e. cachexia (2), a condition which cannot be rescued by conventional nutritional support (3-5). Along with loss of muscle mass, cachectic cancer patients experience loss of muscle strength, as well as cardiac and respiratory failure, altogether contributing to functional impairment and inability to withstand anticancer treatments (6-10). Despite its known debilitating influence on patient outcomes and survival, cachexia remains an understudied field, mainly because of minimal progress on the identification of new pathogenic mechanisms and treatments.

A useful tool to interrogate mechanisms of disease and test therapeutic interventions to combat diseases is the use of small animal models. Unfortunately with respect to cancer cachexia, only a handful of mouse models are currently in use, and their poor molecular characterization represents a major limitation (11-13). Indeed, data on genetic and metabolic profiling are generally missing, with the exception of the Colon-26 (C26) allograft mouse model (14), which remains the most widely used model to study CRC cachexia (15). However, clinical relevance and translational capacity of the current circulating models used for the study of cachexia has been recently questioned. In fact, though cachexia can be detected already during the early stages of tumor progression, it is extremely prominent and highly correlated with advanced metastatic cancers (15), thus corroborating the need for preclinical models of metastatic cancer-induced cachexia. Such need was also recently and elegantly discussed by Tomasin et al., highlighting the fact that the field is still lacking quality, well-characterized and clinically translational models of metastatic cancer cachexia (15). In hopes of meeting this need and advancing the field of cachexia, we and others have employed novel models of CRC-associated LMs, thus taking advantage of intrasplenic injections, which allow for rapid migration of tumor cells to the liver (16-20).

In the present study we sought to thoroughly characterize the skeletal muscle in a model of colorectal LMs using the well-characterized C26 murine cell line. We also assessed the systemic metabolic effects of tumor hosts bearing LMs and examined whether the development of LMs could exacerbate the cachectic phenotype compared to the traditional C26 allograft model. Overall, we aimed at further establishing the importance of developing and utilizing preclinical
models of metastatic cancer to better understand cachexia induced by advanced CRC. Here we demonstrated that metastatic CRC induces dramatic loss of skeletal muscle mass and perturbs energy metabolism. Further, we provided evidence that colorectal LMs exacerbate loss of skeletal muscle mass and strength compared to subcutaneous C26 tumors, thereby highlighting the importance of using preclinical metastatic CRC models to better understand cachexia induced by advanced CRC.
Results

*Formation of colorectal LMs leads to loss of body weight, muscle mass, and muscle strength*

To assess the impact of colorectal LMs on skeletal muscle mass in vivo, CD2F1 male mice were intrasplenically injected with $2.5 \times 10^5$ C26 tumor cells (mC26). This procedure resulted in formation of LMs following liver dissemination via the portal circulation, without generating tumors in extrahepatic organs, such as spleen or lungs. Tumor injected and sham-operated animals were monitored daily for body weight over the course of the experiment. Following tumor cell injection, mC26 hosts experienced progressive weight loss, which resulted in a 16% reduction compared to sham-operated animals ($p < 0.0001$; Figure 1A-B). mC26 hosts saw a non-significant increase in liver size (+21%) compared to sham-operated animals, which can likely be attributed to the localization of C26 tumors within the liver (Figure 1C-E). The loss of body weight was accompanied by wasting in several skeletal muscles including the gastrocnemius (-26%, $p < 0.01$), tibialis anterior (-29%, $p < 0.01$), and quadriceps (-33%, $p < 0.01$) (Figure 2A). The loss of skeletal muscle mass in the mC26 hosts was paralleled by a 25% decline in whole body grip strength ($p < 0.01$; Figure 2B), as well as muscle atrophy, as indicated by reduced tibialis anterior CSA (-22%, $p < 0.05$) (Figure 2C).

*mC26 hosts experience atrophic signaling within skeletal muscle*

To determine if the phenotypic reductions in skeletal muscle mass and weakness were mimicked by disruptions in markers of the anabolic/catabolic balance, we assessed multiple proteins previously implicated in progression of cancer cachexia (14, 21-23). We observed a significant increase in the phospho-STAT3/STAT3 ratio (+136%, $p < 0.0001$), which we have reported in other models of cancer induced cachexia (Figure 3) (14, 23). On the other hand, we witnessed no significant changes in either ERK or p38 phosphorylation. Despite unchanged phospho-AKT/AKT ratio, similar to (23), we did observe reductions in mTOR phosphorylation (-23%, $p < 0.05$), also due to an increase in total mTOR content (+100%) (Figure 3). The reduction in the phospho-mTOR/mTOR ratio was further supported by reductions in its two downstream effectors, phospho-4EBP1 (-58%, $p < 0.05$) and phospho-p70S6K (-45%, $p < 0.05$) (Figure 3). Aside from suppressed markers of anabolic signaling, skeletal muscle from mC26 tumor hosts also experienced heightened markers of protein catabolism including total protein ubiquitination (+142%, $p < 0.01$) and upregulated gene expression of the E3 ubiquitin ligases Atrogin-1 (+671%, $p < 0.001$), MuRF-1 (+2384, $p < 0.05$), and Fbxo31 (+593%, $p < 0.001$) (Figure 4A-B).
mC26 disrupts skeletal muscle mitochondrial homeostasis

We have recently demonstrated that cachexia, as induced by either cancer or chemotherapy, is accompanied by reductions in various mitochondrial proteins required for fusion and biogenesis (23, 24). Therefore, we sought to determine whether disruptions of mitochondrial homeostasis were detected in the mC26 model of cachexia. Here we demonstrate reductions of Mitofusin-2 (-27%, p < 0.01), PGC1α (-15%, p < 0.05) and PGC1β (-44%, p < 0.01) levels in the skeletal muscle of mC26 mice compared to Sham animals (Figure 5A). Meanwhile, we did not witness alterations in protein levels of Cytochrome-C, OPA1, VDAC, Cox IV, or Fis1, or in gene expression levels of Pink1 and Parkin2 (Figure 5A). In line with the reduction seen in mitochondrial proteins, we assessed and determined reduced enzymatic activity of both pyruvate dehydrogenase (PDH; -87%, p < 0.05) and succinate dehydrogenase (SDH; -81%, p < 0.05) (Figure 5B) in mC26 skeletal muscle. This was further complimented by SDH staining of the tibialis anterior muscle, which revealed a shift from oxidative to glycolytic metabolism (+14% glycolytic fibers) in mC26 hosts (Figure 5B). To further examine possible disruption of skeletal muscle energy metabolism we performed Oil Red O staining and found robust increases in intramuscular fat accumulation (Integrated density: +99%, p < 0.01; % Area: +127%, p < 0.001) of mC26 skeletal muscle (Figure 5C).

NMR metabolomics analysis reveals energy perturbations in mC26 hosts

In line with our recent findings showing metabolite changes in skeletal muscle, plasma and liver of mice bearing C26 allografts (25), we aimed to assess if similar perturbations occurred with the formation of C26 LM s. NMR-based metabolomics analysis of skeletal muscle revealed a significant reduction in glucose (-52%, p < 0.05) in the mC26 hosts (Figure 6A). Interestingly, despite the observed alterations in PDH enzyme activity (Figure 5B), skeletal muscle lactate was not significantly changed (Figure 6A). However tricarboxylic acid (TCA) cycle components, succinate and fumarate were reduced by 53% (p < 0.01) and 47% (p < 0.05), respectively, indicating impaired TCA flux of mC26 skeletal muscle (Figure 6A). Interestingly, mC26 hosts displayed increases in isoleucine (+53%, p < 0.01), valine (+51%, P < 0.01), phenylalanine (+156%, p < 0.0001), and the amino acid derivative taurine (+18%, p < 0.0001) (Figure 6B-C). In line with reductions in skeletal muscle glucose, mC26 hosts also displayed reductions in plasma glucose (-49%, p < 0.01) while plasma lactate and pyruvate were unchanged (Figure 7A). In contrast to skeletal muscle, serum branched chain amino acids (BCAAs) leucine (-35%, p < 0.05), isoleucine (-45%, p < 0.01), and valine (-40%, p < 0.01) were reduced in mC26 hosts (Figure 7B). Metabolomics analysis of the liver revealed a dramatic
reduction in glucose (-89%, p < 0.0001) and glycogen (-95%, p < 0.0001) in mC26 hosts, which is in line with an increased systemic demand for glucose (Figure 8, S1). mC26 hosts also displayed significant reductions in liver lactate (-75%, p < 0.001) and alanine (-66%, p < 0.01), likely reflecting an attempt to ramp up gluconeogenesis in order to increase glucose levels. An increase in the ketone body, 3-hydroxybutyrate (+714%, p < 0.01) along with a decrease in NAD+ (-60%, p < 0.01) are consistent with both fatty acid oxidation and an upregulation of gluconeogenesis. We also observed a marked increase in the anapleurotic substrate glutamate (+218%, p < 0.05), and the TCA cycle intermediates fumarate (+92%, p < 0.05) and malate (+99%, p < 0.05) in mC26 hosts suggesting increased flux of liver TCA cycle (Figure 8).

*mC26 hosts have marked cancellous bone loss*

We and others have recently demonstrated that cancer- and chemotherapy-induced skeletal muscle wasting can also be accompanied by disruptions in bone homeostasis, as we previously showed in the ES-2 model of ovarian cancer and in the HT-29 and Apcmin/+ models of CRC (23, 26-28). Interestingly, the traditional C26 allograft model does not present with significant bone disruption (28). Hence, we sought to examine whether the mC26 model drove bone loss in addition to skeletal muscle wasting. To examine cancellous bone morphometry, µCT was performed on femurs from Sham and mC26 tumor bearing mice. mC26 hosts revealed marked reductions in femur cancellous bone. This was evidenced by robust loss of trabecular bone volume fraction (BV/TV; -45%, p < 0.001), thickness (Tb.th; -11%, p < 0.05), number (Tb.N; -37%, p < 0.01) and connectivity density (Conn.Dn; -28%, p < 0.05), while both trabecular separation (Tb.Sp; +51%, p < 0.01) and pattern factor (Tb.pf; +85%, p < 0.01) were increased (Figure 9).

*Formation of colorectal LMs appears to exacerbate skeletal muscle wasting*

Since we observed exacerbated bone loss in the mC26 hosts, not previously identified in allograft C26 tumor hosts, we sought to examine whether formation of colorectal LMs was also responsible for worsened skeletal muscle wasting. In order to interrogate this point, in a separate experiment we transplanted CD2F1 male mice with either subcutaneous C26 allografts or intrasplenic injections to induce LMs (mC26). At time of sacrifice, mC26 animals saw greater reductions in body weight loss compared to the C26 hosts (-2.35 grams; 113% p<0.01) (Figure 10A). Moreover, mC26 mice consistently demonstrated greater reductions than C26 mice in skeletal muscle mass respective to their control littermates, as indicated by reductions in the weight of gastrocnemius (C26: -19%, p < 0.001 vs. Con; mC26: -23%, p < 0.0001 vs. Sham), tibialis anterior (C26: -19%, p < 0.01 vs. Con; mC26: -25%, p < 0.0001 vs. Sham), and especially
quadriceps (C26: -18%, p < 0.001 vs. Con; mC26: -31%, p < 0.0001 vs. Sham; mC26: -20%, p < 0.001 vs. C26) (Figure 10). Interestingly, the hearts of mC26 hosts were also reduced to a greater extent compared to controls (-10%, p < 0.01) than C26 hosts (-7%, p < 0.05) (Figure S2). This was accompanied by greater reductions in cardiac ANP and Myh7b gene expression in mC26 hosts compared to Control (ANP: -61%, p < 0.001; Myh7b: -59%, p < 0.001) and Sham (ANP: -58%, p < 0.001; Myh7b: -62%, p < 0.001) animals than in C26 hosts (ANP: -49% vs. Con, p < 0.01; -46% vs. Sham, p < 0.05; Myh7b: -33% vs. Con, p < 0.05; -38% vs. Sham, p < 0.05) (Figure S2). Moreover, whole body grip strength also revealed a greater reduction in mC26 (-33%, p < 0.01) than C26 (-22%, p < 0.05) mice when compared to their respective experimental controls (Figure 10).

**mC26 and C26 hosts have differentially expressed signaling networks**

As we observed an exacerbated cachectic phenotype in mC26 hosts, we investigated the divergence in gene expression signatures and its associated pathways within skeletal muscle of metastatic and non-metastatic CRC. Next-Generation RNA-seq analysis revealed a large population of commonly shared genes (> 60%), between mC26 and C26, when compared with their respective controls. However, 1227 and 1494 differentially expressed genes were found to be unique to C26 and mC26, respectively (Figure 11A-B). The differentially expressed genes were then used to run pathway and upstream regulator analysis, which revealed both common and differentially altered signaling pathways within C26 and mC26 hosts, as well as distinct upstream regulators (Figure 11 C-D). Interestingly, one of the only altered pathways similar between C26 and mC26 was calcium signaling, revealing that formation of LMs is distinctly altering signaling within skeletal muscle. Identified upstream regulators were also distinct between the two groups, with TLR2 and SOCS1 identified in C26 skeletal muscle and NOS1 and STAT1 identified in mC26 skeletal muscle.
Discussion

According to recent statistics, CRC represents the third most prevalent cancer in the United States and worldwide, and with an estimated 1 in 25 lifetime probability of developing CRC, it remains a major health concern (1). Cachexia, a devastating comorbidity in several types of cancer, including CRC (2), directly contributes to over 20% of cancer-related deaths and is often worsened by anticancer drugs (8-10, 24, 29, 30). We and others have discussed the importance of maintaining lean body mass to improve treatment tolerance and survival outcomes in cancer patients (31). Despite spanning several decades, research efforts have yielded minimal progress towards a cure for cachexia, likely also due to the limited availability of pre-clinical animal models. Indeed, it was recently discussed that minimal change in the use of clinically relevant and translational animal models for the study of cachexia has occurred over the past 10 years (15). This is particularly true when translating current animal models to metastatic cancer cachexia, especially with respect to CRC, in which the C26-bearing mouse remains the most widely used, published and characterized model (15). Given that cachexia is typically observed in the more advanced CRC patients, usually burdened by LMs, it is clear that better and thoroughly characterized models of metastatic CRC cachexia are needed not only to better understand the disease at a mechanistic level, but also in hopes of counteracting the loss of lean mass in order to improve survival (2). In this paper we sought to narrow this pressing gap in the literature by characterizing a metastatic model of CRC cachexia.

In order to mimic the cachectic phenotype of metastatic CRC cachexia, we employed an intrasplenic injection approach to disseminate LMs in vivo by using murine C26 colorectal tumor cells. This particular approach to induce LMs is an accepted state of the art model commonly used in cancer biology and has emerged as a growing area of interest to study cachexia. Though this particular approach has been used previously to demonstrate muscle wasting associated with LMs (16, 18), minimal genetic, metabolic, or molecular alterations of skeletal muscle associated with metastatic CRC have been investigated. In the present study we demonstrated that C26 LMs induce progressive loss of body weight (Figure 1), which was accompanied by severe atrophy of several skeletal muscles and a progressive decline in strength (Figure 2). Moreover, we demonstrated that the skeletal muscle wasting was accompanied by disruptions in skeletal muscle anabolism, catabolism, mitochondrial homeostasis, and energy metabolism.

We and others have implicated STAT3 in cancer-induced muscle wasting in several tumor models, including the C26 allograft and Apcmin/+ CRC models, as well as the Lewis Lung Carcinoma (LLC), B16 melanoma, and ES-2 ovarian
cancer models (14, 21, 23, 32-38). In line with these findings, here we showed a significant increase in STAT3 phosphorylation in mC26 hosts (Figure 3), showing that STAT3 may be a critical prognosticator of cancer-induced muscle atrophy in the presence of C26 metastatic tumors. In line with elevated STAT3 signaling, we also demonstrated heightened protein catabolism, as indicated by increased protein ubiquitination, as well as by elevated expression of the E3 ubiquitin ligases Atrogin-1, MuRF-1, and Fbxo31 (Figure 4), which have been previously reported in association with cachectic muscle, including cachexia associated with LM (18, 23, 39-41). Interestingly, we did not observe alterations in the activation of several other proteins previously described to play a role in cancer cachexia, including ERK (Figure 3), previously showed increased in the skeletal muscle of mice bearing C26 allografts (22). On the other hand, p38 and AKT phosphorylation were found unchanged (22), despite reduced phosphorylation of mTOR and its two downstream effectors, 4EBP1 and p70S6K (Figure 3). This is in line with the work of White et al. that showed reductions in mTOR, 4EBP1, and p70S6K in the Apc^min/+ model of CRC (42). Moreover, the previously mentioned work by Murphy et al. showed no change in phosphorylation of AKT with reduced phosphorylation of p70S6K in animals bearing LM (18).

Quite recently, the role of mitochondria in the sustainment of skeletal muscle mass in cancer cachexia has received much attention. Along this line, we and others have demonstrated that loss of mitochondrial proteins in skeletal muscle of mice bearing cancer or receiving chemotherapy is associated with both loss of muscle mass and strength (23, 24, 43, 44). Moreover, Brown et al. recently demonstrated that mitochondrial dysfunction may actually precede muscle wasting in the LLC model of cachexia, while Xi et al. was able to show that overexpression of Mitofusin-2 could partially sustain skeletal muscle mass in CRC (43, 44). In the present study we showed that mC26 hosts have reduced levels of mitochondrial proteins, including Mitofusin-2, PGC1α and PGC1β (Figure 5), in line with our previously published findings in mice bearing C26 allografts, whereas Cytochrome-C and OPA1 were unchanged (29). Consistent with such impaired mitochondrial homeostasis, we also observed marked reductions in SDH activity. This is also in line with previous findings from ours and other groups showing that cachectic animals bearing cancers or receiving chemotherapy had reduced muscle SDH activity (18, 23, 24).

Given the perturbed skeletal muscle mitochondria we wanted to assess whether mC26 hosts also experienced impaired energy metabolism, both within the skeletal muscle and systemically. We have recently shown disruptions in skeletal muscle and systemic energy metabolism in animals bearing CRC and chemotherapy (25, 45). Our present findings
indicate an increased systemic demand in glucose metabolism as reflected by reduced plasma and skeletal muscle glucose in mC26 hosts (Figures 6 & 7). This is also in line with our previous observations showing reduced plasma glucose in the C26 allograft model (25). Also similar to our previous study, here we showed a reduction in circulating BCAAs, consistent with increased muscle catabolism and subsequent oxidation. Increases in BCAA oxidation have been observed in whole body and skeletal muscle in conditions including sepsis, trauma and after endotoxin or tumor necrosis factor treatment (46-48). Interestingly, in mC26 skeletal muscle we showed elevated isoleucine and valine, consistent with aggressive catabolism of skeletal muscle proteins. Interestingly, TCA intermediates succinate and fumarate are suppressed within mC26 skeletal muscle, implying reduced TCA flux. This is in line with reduced SDH and PDH enzyme activity (Figure 6B), also suggesting impaired oxidative metabolism. The impaired oxidative environment of skeletal muscle is consistent with a shift to glycolysis as the dominant energy producing pathway (Figure 6A).

As the metabolome of both skeletal muscle and plasma of mC26 hosts revealed drastic impairments, we wanted to assess whether the liver was showing similar changes, especially given its robust metabolic flexibility in times of energy stress. Indeed, here we showed that the high systemic demand for glucose demonstrated by plasma and skeletal muscle was also reflected by drastic reductions in liver glucose (Figure 8) and glycogen (Figure S1). These alterations mimic prior data showing reduced liver glucose and glycogen in C26 hosts (25). The liver of mC26 hosts presented significant reductions in the levels of alanine and lactate which is consistent with their use in gluconeogenesis (Figure 8) (25). A dramatic increase in the ketone body 3-hydroxybutyrate (+714%) is consistent with an increase in gluconeogenesis. Under these conditions, the oxaloacetate typically used to condense with Acetyl-CoA to form citrate and feed the TCA cycle, is reduced to malate and continues on the gluconeogenic pathway. The consequent backup of acetyl-CoA from fatty acid β-oxidation thus leads to the formation of 3-hydroxybutyrate. A decrease of NAD+ was observed which is consistent with its consumption in β-oxidation. The TCA cycle intermediates malate and fumarate were markedly increased in the mC26 hosts along with the anaplerotic substrate glutamate suggesting an increase in TCA cycle activity. Significantly increased TCA flux was not clearly evident in the liver of C26 bearers, indicating that tumor infiltration of the liver may induce greater energy perturbations (25).

In line with the need for improved models of metastatic cancer cachexia to further our understanding of the disease, there is also a necessity for better characterization of multiple organs that are negatively affected by different types of
tumors and chemotherapeutics (49). Indeed, examining this organ crosstalk within cachexia may provide important clues to teasing out the mechanisms that drive this morose disease. Our group and others have demonstrated that cancer-induced cachexia does not solely affect skeletal muscle, but that heart, fat, and bone are also impaired (23, 26, 28, 50). In particular, recent observations have implicated that abnormal muscle-bone crosstalk may play a significant role in cancer cachexia. For example observations generated in several mouse models of CRC, including C26, HT-29, and Apcmin/+ revealed differential bone loss, despite consistent loss of skeletal muscle mass (28). Interestingly, cancellous bone in the femurs of C26 tumor hosts was generally maintained, whereas in the present study the use of C26 tumor cells to induce LMs was sufficient to drive both skeletal muscle and bone loss (Figure 9), further indicating an exacerbation in bone phenotype with LMs. Our data also suggest that, since LMs often occur in advanced CRC patients, examination of bone mineral density should be warranted, especially considering that heightened bone loss can further contribute to muscle loss and weakness (50).

Given the finding that bone loss occurred in mC26 hosts, compared to a normal bone phenotype in mice bearing subcutaneous C26 tumors, we sought to understand whether skeletal muscle loss was also exacerbated in metastatic tumor bearing hosts. In a follow-up experiment involving a direct comparison among mice bearing C26 allograft and mice carrying mC26 tumors, we demonstrated greater losses in body weight, skeletal muscle mass, cardiac size, as well as whole body grip strength in the presence of LMs, with the quadriceps muscle 20% smaller in mC26 compared C26 tumor hosts (Figure 10; S2). This exacerbated wasting occurred in the animals with CRC LMs, despite the fact that the mC26 hosts initially received fewer tumor cells compared to the C26 bearers (2.5 x 10^5 vs. 1.0 x 10^6, respectively). This is important to note as it implicates the site of injection as a critical prognosticator for the development of cachexia, as also previously demonstrated in work by Chiba et al. (51). Nonetheless, that study did not take into exam the impact of LMs. To understand the pathways that may potentially lead to this exacerbation, we performed RNA sequencing on quadriceps muscles. We found that over 60% of genes altered in mC26 and C26 hosts were similar, including known prognosticators of muscle wasting such as STAT3, MucRF-1, Atrogin-1, FBXO31, and PDK4 (14, 21, 39-41, 52). However, the fold-change elevation of these genes tended to be generally greater in mC26 hosts (STAT3: 5.6 vs. 4.6; MucRF-1: 25 vs. 20; Atrogin-1: 14 vs. 13.9; FBXO31: 6 vs. 6.2; PDK4: 8.7 vs. 5.7), which may in part explain the worsened muscle wasting. Follow-up pathway analysis performed using the differentially expressed genes identified several differentially regulated pathways as well as differential upstream regulators within mC26 and C26 tumor hosts (Figure 11D-E.). Several of the modulated pathways including calcium,
sirtuin, STAT3, PTEN, and oxidative phosphorylation, have been implicated in muscle wasting diseases (14, 21, 23, 25, 53-55). The identified C26 regulator TLR2 has previously shown to mediate myotube atrophy, although in the present context TLR2 was found to be down-regulated (56). We also identified STAT1 as an upstream regulator within mC26 skeletal muscle. Interestingly, STAT1 has recently been implicated as a regulator of autophagy, a degradation process known to be upregulated in cachectic cancer patients and animal models of cachexia (57-59). Future studies will interrogate these pathways to better understand the mechanisms by which formation of LMs differentially alter skeletal muscle signaling.

Overall, our study clearly demonstrates that formation of LMs induces, and even aggravates, muscle atrophy induced by CRC. Though we examined and identified differential signaling networks within skeletal muscle of tumor hosts bearing LMs, investigation into how CRC metastases alter the liver endocrine function and how this may ultimately influence skeletal muscle wasting was not explored in the current study. Additionally, tumor burden in the mC26 model was crudely assessed using only histological analysis, thus possibly representing a limitation of our approach and preventing us from performing a direct comparison with tumor size in the C26 hosts. Given the search for more translationally relevant models, another limitation of the present study is the shortened nature in the development of cachexia. Though the goal of the study to examine cachexia in a context of CRC LM was achieved, future studies may consider using lower doses of C26 tumor cells or perhaps other CRC cells that may allow the progression of cachexia to extend beyond 2 weeks. Moreover, in the present study we did not take into consideration whether the administration of chemotherapeutics further aggravate muscle wasting, especially considering that our lab and others have demonstrated that several anticancer compounds induce cachexia independent of their effects on tumor growth (24, 26, 27, 29, 30, 60). Lastly, another limitation of the current study was the focus on male animals, leaving out possible sex differences in response to LMs. As sexual dimorphism has been identified in other models of CRC, future studies should examine how LMs influence skeletal muscle in males vs. females (33).

In conclusion, we have demonstrated that formation of C26 CRC LMs induces robust skeletal muscle atrophy. Skeletal muscle atrophy in mC26 hosts was accompanied by elevated protein catabolism, disrupted mitochondrial homeostasis, and perturbed skeletal muscle metabolism. Formation of C26 LMs also leads to systemic alterations in energy metabolism and impaired bone homeostasis. Moreover, formation of C26 LMs aggravates cachexia and induces
differential gene expression within skeletal muscle compared CRC cachexia induced by C26 subcutaneous tumors.

Overall, our study provides support for the use of in vivo metastatic models for the study of cancer cachexia.
Methods

Cell lines

Prior to conducting animal work, Colon-26 (C26) cells, provided by Donna McCarthy (Ohio State University), were cultured in DMEM medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% sodium pyruvate and maintained in a 5% CO2, 37°C humidified incubator. C26 cells were cultured, passaged, and trypsinized when sub-confluent to be prepared for animal injection in sterile saline.

Animals

For the colorectal liver metastases model we utilized methods previously employed by our lab and others (16-20, 61). Briefly, 12-week-old CD2F1 male mice were placed under anesthesia and a side subcostal incision was made to carefully expose the spleen. Animals were then intrasplenically injected with 100µl of saline containing 2.5 x 10⁵ C26 tumor cells (mC26), or saline alone (Sham) over the period of 1 minute, followed by 2 minutes of hemostasis (n = 5/group). The intrasplenic injection approach allows for tumor cells to quickly enter the portal circulation, thus infiltrating the liver, without forming tumors in the spleen or other common metastatic sites of CRC, such as the lung. In a separate experiment 8-week old CD2F1 male mice were either intrasplenically (mC26; 2.5 x 10⁵) or subcutaneously (C26; 1.0 x 10⁶) injected with C26 cells (n = 4-6/group) (62). Non-tumor bearing (Con) and sham-operated (Sham) mice were used as controls. Mice were weighed daily, then euthanized under light isoflurane anesthesia. At the time of sacrifice, skeletal muscle tissues were harvested, weighed, then snap frozen in liquid nitrogen and stored at −80°C for further studies. The tibialis anterior muscles were frozen in liquid nitrogen-cooled isopentane for histology, as previously described (23). All mouse carcasses, including a portion of the liver were fixed for two days in 10% neutral buffered formalin and then transferred into 70% ethanol.

Whole-body Grip Strength Assessment

Whole-body grip strength was assessed using a commercially available automatic grip strength meter (Columbus Instruments, Columbus, OH, USA) as previously shown (63). The absolute force (expressed in grams) was recorded over five measurements, with the top three measurements utilized for analysis. To further avoid habituation bias, animals were only tested once a week during the experimental period.
**Hematoxylin and eosin (H&E) Staining**

To examine the formation of liver metastases, fixed liver tissue was paraffin embedded and sectioned (10 μm) in preparation for H&E staining (23). Stained liver sections were then observed under an Axio Observer.Z1 motorized microscope (Zeiss, Oberchoken, Germany) and 5x images were recorded for tumor infiltration assessment. Using ImageJ 1.43 software, images were assessed for the tumor area relative to liver area (expressed as a percentage).

**Muscle Cross-sectional Area (CSA)**

To assess skeletal muscle atrophy, 10 μm-thick cryosections of tibialis anterior muscles, taken at the mid-belly, were processed for immunostaining as described previously (30). Briefly, sections were blocked for one hour at room temperature and incubated overnight at 4°C with a dystrophin primary antibody (Developmental Studies Hybridoma Bank, Iowa City, IA, USA; #MANDRA1(7A10)), followed by a one-hour secondary antibody (AlexaFluor 594 # A-11032; Thermo Fisher Scientific, Waltham, MA, USA) incubation at room temperature. Entire dystrophin stained sections were analyzed for CSA using Lionheart LX automated microscope (BioTek Instruments, Winooski, VT, USA).

**Western Blotting**

Skeletal muscle protein extracts were obtained by homogenizing 50 mg of quadriceps muscle tissue in RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) supplemented with inhibitor cocktails for proteases (Roche, Indianapolis, IN, USA) and phosphatases (Thermo Scientific, Rockford, IL, USA). Cellular debris was removed by centrifugation (15 min, 14,000× g at 4°C), the supernatant was collected, and protein concentration was determined using the BCA protein assay method (Thermo Scientific). Protein extracts (30 μg) were then electrophoresed in 4–15% gradient SDS Criterion TGX precast gels (Bio-Rad, Hercules, CA, USA), followed by gel transfer to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with SEA BLOCK blocking reagent (Thermo Scientific) at room temperature for 1 h, followed by an overnight incubation with diluted antibody in SEA BLOCK buffer (Thermo Scientific) containing 0.2% Tween-20 at 4 °C with gentle shaking. After washing with PBS containing 0.2% Tween-20 (PBST), the membrane was incubated at room temperature for 1 h with either anti-rabbit IgG (H+L) DyLight 800 or anti-mouse IgG (H+L) DyLight 680 secondary antibodies (Cell Signaling Technologies, Danvers, MA, USA). Blots were then visualized and quantified using the
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Antibodies used were phospho-STAT3 (Tyr705) (#9145), STAT3 (#12640), phospho-ERK1/2 (Thr202/Tyr204) (#4370), ERK1/2 (#4695), phospho-p38 (Thr180/Tyr182) (#4511), p38 (#9212), phospho-AKT (Ser473) (#4060), AKT (#9272), phospho-mTOR (Ser2448) (#5536), mTOR (#2983), phospho-4EBP1 (Thr37/46) (#2855), 4EBP1 (#9644), phospho-p70S6K (Thr389) (#9234), p70S6K (9209), Ubiquitin (#3933), Mitofusin-2 (#9482), Cytochrome C (#11940), OPA-1 (#80471), COX IV (#4844), VDAC (#4866), GAPDH (#97166), from Cell Signaling Technologies, PGC-1α (#AB3242) from MilliporeSigma (Burlington, MA, USA), PGC-1β (#ab176328) from Abcam (Cambridge, MA, USA), FIS1 (#10956-1-AP) from Proteintech (Rosemont, IL, USA) and α-Tubulin (#12G10) from Developmental Studies Hybridoma Bank (Iowa City, IA, USA). In general, phosphorylated protein levels were normalized to the expression of the respective total proteins and tubulin or GAPDH was used as loading control.

Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR)

RNA from quadriceps muscle was isolated using the miRNeasy Mini kit (Qiagen, Valencia, CA, USA), following the protocol provided by the manufacturer. RNA was quantified using a Synergy H1 spectrophotometer (BioTek, Winooski, VT, USA). Total RNA was reverse transcribed to cDNA using the Verso cDNA kit (Thermo Fisher Scientific, Waltham, MA, USA). Transcript levels were measured by Real-Time PCR (Light Cycler 96, Roche, Indianapolis, IN, USA) taking advantage of the TaqMan gene expression assay system (Life Technologies, Carlsbad, CA, USA). Expression levels for Atrogin1 (Mm00499523_m1), MuRF1 (Mm01185221_m1), Fbxo31 (Mm00505343_m1), Pink1 (Mm00550827) Park2 (Mm00450187), ANP (Mm01255747), BNP (Mm01255770), and Myh7b (Mm1249941) were detected. Gene expression was normalized to TBP (Mm01277042_m1) levels using the standard 2−ΔΔCT methods.

Pyruvate Dehydrogenase (PDH) and Succinate Dehydrogenase (SDH) Enzymatic Activity

The enzymatic activities of PDH and SDH were measured using Colorimetric Assay Kits (MAK051 and MAK197, respectively) from MilliporeSigma based on the manufacturer’s instructions. Briefly, 10 mg of quadriceps muscle was homogenized in 100 μl of ice-cold assay buffer followed by centrifugation. 10 μl of sample supernatant was added to 96-well plates. PDH and SDH reaction mixes were added to appropriate wells, resulting in a colorimetric (450nm for PDH and 600nm for SDH) product proportional to the enzymatic activity. The absorbance was recorded by incubating the plate (37°C for PDH and 25°C for SDH) and taking measurements (450 nm and 600nm) every 5 min for 30 min.
**SDH Staining**

Tibialis anterior muscles were cut into 10μm cross-sections on a cryostat and incubated for 30 min at 37°C with 0.5 mg/ml nitroblue tetrazoliumand, 50 mM Na-succinate, and 0.08 mM phenazine methosulfate in PBS. Sections were then rinsed 3 times in deionized water, mounted with PBS-glycerol, and photographed using an Axio Observer.Z1 motorized microscope (Carl Zeiss). Entire SDH-stained sections were quantified for integrated density, as well as total, oxidative, and glycolytic fiber number using ImageJ software.

**Oil Red O (ORO) Staining**

For ORO staining, tibialis anterior muscles were sectioned (10μm) and immediately fixed in ice cold formaldehyde (3.7%) for 1 hour. Sections were serially washed in Milli-Q water and stained in ORO working solution (prepared as previously described (64)) for 45 minutes at room temperature in the dark. Following ORO staining, sections were again serially washed in Milli-Q water then rinsed in running tap water for 10 minutes. Sections were mounted in 50% glycerol (in PBS) and photographed using an Axio Observer.Z1 motorized microscope (Zeiss, Oberhoken, Germany). Entire ORO stained sections were analyzed for signaling intensity and area of positive staining using ImageJ software.

**Metabolomics Analysis by Nuclear Magnetic Resonance (NMR)**

Plasma samples for NMR analysis were prepared by diluting 100 μL of plasma with 500 μL of a deuterated phosphate buffer solution (pH = 7.4) containing 2,2,-dimethyl-2-silapentane-5-sulfonate sodium salt (DSS) with a final concentration of 0.5 mM to be used as a chemical shift and quantitation reference. The solution was filtered through a 10 KDa molecular weight cut-off filter to remove large proteins. Samples were then placed in 5 mm NMR tubes for analysis. Muscle and liver tissues for NMR analysis were prepared according to the methanol/chloroform water procedure as previously performed (25). Tissue samples of ~100 mg were used for all samples, but actual weights were recorded to normalize the data. NMR data were acquired on a Bruker Avance III 700 MHz NMR spectrometer with a TXI triple resonance probe operating at 25°C. Spectra were collected with a 1D NOESY pulse sequence covering 12 ppm. The spectra were digitized with 32,768 points during a 3.9 s acquisition time. The mixing time was set to 100 ms, and the relaxation delay between scans was set to 2.0 s. All data were then processed using Advanced Chemistry Development Spectrus Processor (version 2016.1; Toronto, Canada). The spectra were zero filled to 65,536
points and apodized using a 0.3 Hz decaying exponential function and fast Fourier transformed. Automated phase correction and first-order baseline correction were applied to all samples. Metabolite concentrations were quantified using the Chenomx NMR Suite (version 8.2; Edmonton, Canada). The DSS-d6 was used as a chemical shift and quantification reference for all spectra and was set to a chemical shift of 0.00 and a concentration of 500 μM. Quantitative fitting of each spectrum was carried out in batch mode, followed by manual adjustments to correct for errors arising from spectral overlap. For tissue samples, the final concentrations were normalized based on the weight of the tissue used to prepare each sample. The quantification of glycogen in liver tissue was carried out using a colorimetric Glycogen Assay Kit II (Abcam, Cambridge, USA, #ab16955), per manufacturer’s instructions.

*Microcomputed Tomography Analysis of Femur Bone Morphometry*

MicroCT scanning was performed to measure morphological indices of metaphyseal regions of femurs. After euthanasia, the left femurs were wrapped in saline-soaked gauze and frozen at -20ºC until imaging. Bone samples were rotated around their long axes and images were acquired using a Bruker Skyscan 1176 (Bruker, Kontich, Belgium) with the following parameters: pixel size = 9 μm³; peak tube potential = 50 kV; X-ray intensity = 500 μA; 0.3° rotation step. Calibration of the greyscale levels was performed using a hydroxyapatite phantom. Based on this calibration and the corresponding standard curve generated, the equivalent minimum calcium hydroxyapatite level is 0.42 g/cm³. Raw images were reconstructed using the SkyScan reconstruction software (NRecon; Bruker, Kontich, Belgium) to 3-dimensional cross-sectional image data sets using a 3-dimensional cone beam algorithm. Structural indices were calculated on reconstructed images using the Skyscan CT Analyzer software (CTAn; Bruker, Kontich, Belgium). Cortical bone was analyzed by threshold of 160–255 in the femoral mid-shaft. Cortical bone parameters included periosteal perimeter (Ps.Pm), bone area/tissue area (BA/TA), cortical thickness (Ct.Th) and cortical porosity (Ct.Po). Trabecular bone was analyzed between 1.0 mm to 2.0 mm under the femoral distal growth plate using a threshold of 80–255. Trabecular parameters included bone volume fraction (BV/TV), number (Tb.N), thickness (Tb.Th), separation (Tb.Sp), and pattern factor (Tb.Pf).

*RNA Sequencing*

Total RNA was first evaluated for its quantity, and quality, using Agilent Bioanalyzer 2100. For RNA quality, a RIN number of 7 or higher is desired. Fifty nanograms of total RNA was used. cDNA library preparation included mRNA
purification/enrichment, RNA fragmentation, cDNA synthesis, ligation of index adaptors, and amplification, following the KAPA mRNA Hyper Prep Kit Technical Data Sheet, KR1352 – v4.17 (Roche Corporate). Each resulting indexed library was quantified and its quality accessed by Qubit and Agilent Bioanalyzer, and multiple libraries pooled in equal molarity. Five microliters of 2 nM pooled libraries per lane were denatured, neutralized and applied to the cBot for flow cell deposition and cluster amplification, before loading to HiSeq 4000 for 75b paired-end sequencing (Illumina, Inc.). Approximately 30M reads per library were generated. A Phred quality score (Q score) was used to measure the quality of sequencing. More than 90% of the sequencing reads reached Q30 (99.9% base call accuracy).

The sequencing data were first assessed using FastQC (Babraham Bioinformatics, Cambridge, UK) for quality control. Then all sequenced libraries were mapped to the mouse genome (mm10) using STAR RNA-seq aligner (65) with the following parameter: “--outSAMmapqUnique 60”. The reads distribution across the genome was assessed using bamutils (from ngsutils) (66). Uniquely mapped sequencing reads were assigned to mm10 refGene genes using featureCounts (from subread) (67) with the following parameters: “-s 2 -p -Q 10”. Quality control of sequencing and mapping results was summarized using MultiQC (68). Genes with read count per million (CPM) < 0.5 in more than 4 of the samples were removed. The data was normalized using TMM (trimmed mean of M values) method. Differential expression analysis was performed using edgeR (69). False discovery rate (FDR) was computed from p-values using the Benjamini-Hochberg procedure. The heatmap was generated using Partek Flow genomic analysis software (St. Louis, Missouri, USA). Ingenuity pathway analysis (IPA) software was used to identify the canonical pathways and upstream regulators. Pathways with p<0.05 were considered significant. We only considered the upstream molecules that were differentially expressed in our dataset. We considered the pathways which had any z-score. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE142455 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142455) (70).

**Statistical Analysis**

T-tests were used to determine differences between Sham and mC26 groups for figures 1-9. One-way analysis of variance (ANOVA) tests were performed to determine differences between Con, C26, Sham, and mC26. Post-hoc comparisons were accomplished via a Tukey’s test, with statistical significance set a priori at p ≤ 0.05. All statistics were performed using GraphPad Prism 7.04 and all data are presented as means ± SD.
Study approval

All studies were in compliance with the National Institutes of Health Guidelines for the use and care of Laboratory Animals and with the 1964 Declaration of Helsinki and its later amendments. Further, the studies were conducted in line and with approval of the Institutional Animal Care and Use Committee at Indiana University School of Medicine (IU IACUC protocol #11275).
Authors contributions

JRH, LJN and AB conceived and designed the experiments; JRH, LJN, and FP performed the in vivo experiments, grip strength analysis, and molecular characterization of cachexia; TMO analyzed the metabolomics data; JRH, AN, TAZ and AB analyzed the RNA sequencing data; JRH, TMO, and AB wrote and edited the paper.
Acknowledgments

This study was supported by the Department of Surgery and the Department of Otolaryngology – Head & Neck Surgery at Indiana University, by grants from the National Cancer Institute (R01CA122596, R01CA194593), the Veterans Administration (1I01-BX004177-01), the Lustgarten Foundation, the IU Simon Cancer Center (NIH P30CA082709) to TAZ, and by grants from the Showalter Research Trust, the V Foundation for Cancer Research (V2017-021), the American Cancer Society (Research Scholar Grant 132013-RSG-18-010-01-CCG) to AB. The #12G10 anti-Tubulin monoclonal antibody (developed by Frankel J and Nelsen EM at University of Iowa) and the #MANDRA1(7A10) anti-Dystrophin monoclonal antibody (developed by Morris GE at NE Wales Institute) were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA.
References

1. Siegel RL, Miller KD, and Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70(1):7-30.
2. Ruers T, and Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. *Eur J Cancer*. 2002;38(7):1023-33.
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol.* 2011;12(5):489-95.
4. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* 2012;62(1):10-29.
5. Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. *Clin Nutr.* 2013;32(1):65-72.
6. Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, and Roeland EJ. Cancer Cachexia: Beyond Weight Loss. *J Oncol Pract.* 2016;12(11):1163-71.
7. Fearon KC, Glass DJ, and Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metab.* 2012;16(2):153-66.
8. Barton BE. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. *Immunol Res.* 2001;23(1):41-58.
9. Loberg RD, Bradley DA, Tomlins SA, Chinnaian AM, and Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due to malignancy. *CA Cancer J Clin.* 2007;57(4):225-41.
10. Tisdale MJ. Mechanisms of cancer cachexia. *Physiol Rev.* 2009;89(2):381-410.
11. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. *BMC Cancer.* 2010;10:363.
12. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, and Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. *Biochem Biophys Res Commun.* 2010;391(3):1548-54.
13. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O, et al. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. *Cancer Res.* 1991;51(24):6656-9.
14. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniariis LG, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. *PLoS One.* 2011;6(7):e22538.

15. Tomasin R, Martin A, and Cominetti MR. Metastasis and cachexia: alongside in clinics, but not so in animal models. *J Cachexia Sarcopenia Muscle.* 2019.

16. Huot JR, Novinger LJ, Pin F, and Bonetto A. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. *Dis Model Mech.* 2020.

17. Kuruppu D, Christophi C, Bertram JF, and O’Brien PE. Characterization of an animal model of hepatic metastasis. *J Gastroenterol Hepatol.* 1996;11(1):26-32.

18. Murphy KT, Struk A, Malcontenti-Wilson C, Christophi C, and Lynch GS. Physiological characterization of a mouse model of cachexia in colorectal liver metastases. *Am J Physiol Regul Integr Comp Physiol.* 2013;304(10):R854-64.

19. Xu H, Zhang Y, Pena MM, Pirisi L, and Creek KE. Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages. *Carcinogenesis.* 2017;38(3):281-92.

20. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, et al. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringleles. *Cancer Res.* 2004;64(19):7092-8.

21. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. *Am J Physiol Endocrinol Metab.* 2012;303(3):E410-21.

22. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, and Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. *PLoS One.* 2010;5(10):e13604.

23. Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. *J Cachexia Sarcopenia Muscle.* 2018;9(4):685-700.

24. Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, and Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. *Oncotarget.* 2016;7(28):43442-60.
25. Pin F, Barreto R, Couch ME, Bonetto A, and O'Connell TM. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. *J Cachexia Sarcopenia Muscle*. 2019;10(1):140-54.

26. Barreto R, Kitase Y, Matsumoto T, Pin F, Colston KC, Couch KE, et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. *Sci Rep*. 2017;7(1):14470.

27. Hain BA, Xu H, Wilcox JR, Mutua D, and Waning DL. Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. *JCSM Rapid Commun*. 2019;2(1).

28. Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, et al. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. *Front Physiol*. 2016;7:679.

29. Barreto R, Mandili G, Witzmann FA, Novelli F, Zimmers TA, and Bonetto A. Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. *Front Physiol*. 2016;7:472.

30. Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, et al. Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. *Cancers (Basel)*. 2019;11(4).

31. Pin F, Couch ME, and Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. *Curr Opin Support Palliat Care*. 2018;12(4):420-6.

32. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, and Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. *Am J Physiol Regul Integr Comp Physiol*. 2008;294(2):R393-401.

33. Hetzler KL, Hardee JP, Puppa MJ, Narsale AA, Sato S, Davis JM, et al. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression. *Biochim Biophys Acta*. 2015;1852(5):816-25.

34. Narsale AA, Enos RT, Puppa MJ, Chatterjee S, Murphy EA, Fayad R, et al. Liver inflammation and metabolic signaling in ApcMin/+ mice: the role of cachexia progression. *PLoS One*. 2015;10(3):e0119888.

35. Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, et al. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. *Oncotarget*. 2015;6(5):3043-54.

36. Puppa MJ, Gao S, Narsale AA, and Carson JA. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia. *FASEB J*. 2014;28(2):998-1009.
37. Silva KA, Dong J, Dong Y, Schor N, Tweeker DJ, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. *J Biol Chem.* 2015;290(17):11177-87.

38. Zimmers TA, Fishel ML, and Bonetto A. STAT3 in the systemic inflammation of cancer cachexia. *Semin Cell Dev Biol.* 2016;54:28-41.

39. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, et al. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. *Cancer Res.* 2004;64(22):8193-8.

40. Milan G, Romanello V, Pescatore F, Armani A, Paik JH, Frasson L, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. *Nat Commun.* 2015;6:6670.

41. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell.* 2004;117(3):399-412.

42. White JP, Baynes JW, Welle SL, Kostek MC, Matesic LE, Sato S, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min+/+) mouse. *PLoS One.* 2011;6(9):e24650.

43. Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, Perry RA, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. *J Cachexia Sarcopenia Muscle.* 2017;8(6):926-38.

44. Xi QL, Zhang B, Jiang Y, Zhang HS, Meng QY, Chen Y, et al. Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. *Oncol Lett.* 2016;12(5):4013-20.

45. O'Connell TM, Pin F, Couch ME, and Bonetto A. Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia. *Cancers (Basel).* 2019;11(9).

46. Beck SA, and Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. *Cancer Res.* 1989;49(14):3800-4.

47. Cala MP, Agullo-Ortuno MT, Prieto-Garcia E, Gonzalez-Riano C, Parrilla-Rubio L, Barbas C, et al. Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study. *J Cachexia Sarcopenia Muscle.* 2018;9(2):348-57.
48. Sthoeger Z, Zinger H, Sharabi A, Asher I, and Mozes E. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-alpha in murine and human systemic lupus erythematosus. *PLoS One.* 2013;8(3):e60394.

49. Porporato PE. Understanding cachexia as a cancer metabolism syndrome. *Oncogenesis.* 2016;5:e200.

50. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. *Nat Med.* 2015;21(11):1262-71.

51. Chiba F, Soda K, Yamada S, Tokutake Y, Chohnan S, Konishi F, et al. The importance of tissue environment surrounding the tumor on the development of cancer cachexia. *Int J Oncol.* 2014;44(1):177-86.

52. Pin F, Novinger LJ, Huot JR, Harris RA, Couch ME, O’Connell TM, et al. PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. *FASEB J.* 2019;33(6):7778-90.

53. Shen J, Nie X, Huang SY, Qin YQ, Pan LL, and Wang XT. Neuromuscular electrical stimulation improves muscle atrophy induced by chronic hypoxia-hypercapnia through the MicroRNA-486/PTEN/FoxO1 pathway. *Biochem Biophys Res Commun.* 2019;509(4):1021-7.

54. Toledo M, Busquets S, Ametller E, Lopez-Soriano FJ, and Argiles JM. Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? *J Cachexia Sarcopenia Muscle.* 2011;2(1):57-62.

55. Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, et al. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model. *Front Endocrinol (Lausanne).* 2017;8:358.

56. Hahn A, Kny M, Pablo-Tortola C, Todiras M, Willenbrock M, Schmidt S, et al. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. *J Cachexia Sarcopenia Muscle.* 2019.

57. Aversa Z, Pin F, Lucia S, Penna F, Verzaro R, Fazi M, et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. *Sci Rep.* 2016;6:30340.

58. Goldberg AA, Nkengfac B, Sanchez AM, Moroz N, Qureshi ST, Koromilas AE, et al. Regulation ofULK1 Expression and Autophagy by STAT1. *J Biol Chem.* 2017;292(5):1899-909.

59. Penna F, Ballaro R, Martinez-Cristobal P, Sala D, Sebastian D, Busquets S, et al. Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. *J Mol Biol.* 2019;431(15):2674-86.
60. Hain BA, Jude B, Xu H, Smuin DM, Fox EJ, Elfar JC, et al. Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. *J Bone Miner Res.* 2019.

61. Brand MI, Casillas S, Dietz DW, Milsom JW, and Vladisavljevic A. Development of a reliable colorectal cancer liver metastasis model. *J Surg Res.* 1996;63(2):425-32.

62. Bonetto A, Rupert JE, Barreto R, and Zimmers TA. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia. *J Vis Exp.* 2016(117).

63. Bonetto A, Andersson DC, and Waning DL. Assessment of muscle mass and strength in mice. *Bonekey Rep.* 2015;4:732.

64. Peck B, Huot J, Renzi T, Arthur S, Turner MJ, and Marino JS. Mice lacking PKC-theta in skeletal muscle have reduced intramyocellular lipid accumulation and increased insulin responsiveness in skeletal muscle. *Am J Physiol Regul Integr Comp Physiol.* 2018;314(3):R468-R77.

65. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15-21.

66. Breese MR, and Liu Y. NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets. *Bioinformatics.* 2013;29(4):494-6.

67. Liao Y, Smyth GK, and Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923-30.

68. Ewels P, Magnusson M, Lundin S, and Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics.* 2016;32(19):3047-8.

69. Robinson MD, McCarthy DJ, and Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139-40.

70. Edgar R, Domrachev M, and Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002;30(1):207-10.
Figure 1. mC26 tumor hosts experience a significant body weight (BW) reduction. (A) BW curves in CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). (B) Net BW change (initial to final), expressed in grams. (C) Liver weights (normalized to initial body weight (IBW)), (D) Representative whole liver and H&E staining of liver from Sham and mC26 mice. Black arrows indicate tumors and images were taken at 20x magnification. (E) Quantification of relative tumor area within livers from Sham and mC26 mice. Data are expressed as mean ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: ****p<0.0001 vs. Sham.
Figure 2. mC26 induces muscle atrophy and weakness. (A) Muscle weights normalized to initial body weight (IBW) in CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). (B) Weekly whole body grip strength assessment (expressed in grams). (C) Cross-sectional area (CSA) of entire tibialis anterior muscles and representative CSA image of tibialis anterior muscle sections stained with anti-dystrophin antibody. Scale bar equals 100 µm. Data are expressed as mean ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01 vs. Sham.
**Figure 3.** **mC26 disrupts skeletal muscle anabolism.** Representative western blotting and quantification (expressed as fold change vs. Sham) for phospho-STAT3, STAT3, phospho-ERK1/2, ERK1/2, phospho-p38, p38, phospho-AKT, AKT, phospho-mTOR, mTOR, phospho-4EBP1, 4EBP1 (blot 1) and for phospho-p70S6K, p70S6K (blot 2) in the muscle of CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). Tubulin was used as loading control in both blots. Quantification of phospho/total protein ratios are reported as mean ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ****p<0.0001 vs. Sham.
**Figure 4. Increased protein catabolism in mC26 mice.** (A) Representative western blotting and quantification (expressed as fold change vs. Sham) for total ubiquitin and tubulin in CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). Tubulin was used as loading control. (B) Gene expression levels for Atrogin-1, MuRF-1, and Fbxo31 ubiquitin ligases measured by quantitative real-time PCR. Gene expression was normalized to TBP levels. Data are expressed as mean ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ***p<0.001 vs. Sham.
Figure 5. Skeletal muscle of mC26 mice displays disrupted mitochondrial function. (A) Representative western blotting and quantification (expressed as fold change vs. Sham) for Mitofusin-2, Cytochrome-C and PGC1α (blot 1; GAPDH used as loading control), as well as for PGC1β, OPA1, VDAC, CoxIV, Fis1 (blot 2; tubulin used as loading control) in the muscle of CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). Gene expression levels for Pink1 and Park2 measured by quantitative real-time PCR and normalized to TBP levels. (B) Enzymatic activity for pyruvate dehydrogenase (PDH) and succinate dehydrogenase (SDH) and SDH staining and quantification on tibialis anterior muscles. (C) Oil red o (ORO) staining and quantification of tibialis anterior muscles. Images were captured at a magnification of 20X. Data are expressed as means ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ***p<0.001 vs. Sham.
Figure 6. Skeletal muscle of mC26 hosts display compromised metabolome. (A) Representative diagram of glycolysis and tricarboxylic acid (TCA) cycle showing metabolite concentrations (mM) in skeletal muscle of CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=4). (B) Branch chain amino acid (Leucine, Isoleucine, and valine) concentrations expressed in mM and (C) Glycine, Phenylalanine, and Taurine concentrations (in mM) of sham and mC26 hosts. Data are expressed as means ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ***p < 0.001, ****p<0.0001 vs. Sham.
Figure 7. mC26 mice exhibit systemic shifts in metabolism. Representative diagram of glycolysis showing metabolite concentrations (mM) in serum of CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=4-5). (B) Serum branch chain amino acid (Leucine, Isoleucine, and valine) concentrations (mM) of Sham and mC26 hosts. Data are expressed as means ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01 vs. Sham.
Figure 8. **mC26 hosts have altered liver metabolome.** Representative diagram of glycolysis and tricarboxylic acid (TCA) cycle showing metabolite concentrations (mM) in livers of CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=4-5). Data are expressed as means ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ***p < 0.001, ****p<0.0001 vs. Sham.
Figure 9. Formation of colorectal liver tumors affects trabecular bone. Representative three-dimensional rendering of μCT scanned images and quantification of bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), trabecular pattern factor (Tb.pf), and trabecular connectivity density (Conn.Dn) of femur bones from CD2F1 male mice (12-week old) intrasplenically injected with C26 tumor cells (250,000 cells/mouse in sterile PBS: mC26) or an equal volume of vehicle (Sham) (n=5). Data are expressed as means ± SD. T-tests were used to determine differences between Sham and mC26. Significance of the differences: *p<0.05, **p<0.01, ***p<0.001 vs. Sham.
Figure 10. Colorectal liver metastases exacerbate muscle wasting and weakness. (A) Body weight (BW) change (vs. initial body weight) at time of sacrifice, expressed in grams, (B) Muscle weights normalized to initial body weight (IBW) and (C) whole body grip strength assessment (expressed in grams) in CD2F1 male mice (8-week old) either injected with C26 tumor cells subcutaneously (1,000,000 cells/mouse in sterile PBS: C26) or intrasplenically (250,000 cells/mouse in sterile PBS: mC26). Control (Con for C26) and Sham (controls for mC26) were injected with an equal volume of vehicle (n=4-6). Data are expressed as mean ± SD. One-way analysis of variance (ANOVA) tests were performed to determine differences between Con, C26, Sham, and mC26. Significance of the differences: #p<0.05, ###p<0.001, ####p<0.0001 vs. Con; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs. Sham; $$p<0.01, $$$p<0.001 vs. C26.
Figure 11. RNA sequencing analysis of skeletal muscle reveals differentially expressed genes in C26 and mC26 mice. Next-Generation RNA-sequencing was performed on whole RNA extracted from skeletal muscle of CD2F1 male mice (8-week old) either injected with C26 tumor cells subcutaneously (1,000,000 cells/mouse in sterile PBS: C26) or intrasplenically (250,000 cells/mouse in sterile PBS: mC26). Control (Con for C26) and Sham (controls for mC26) were injected with an equal volume of vehicle (n=5-6). (A) Heatmap representing the full list of differentially expressed genes in both C26 and mC26 skeletal muscle. Cut-offs for genes were fold-change of 1.5 and a false discovery rate of 0.05. (B) Differential expression analysis identified 4277 common genes between C26 and mC26 along with several unique genes. Square dots indicate -Log10 p-value (C) Top 10 representative pathways: Analysis was performed using the unique genes from C26 (1227 genes) and mC26 (1494 genes). Blue indicates the pathways identified in C26 and red indicates the pathways in mC26. (D and E) Upstream regulators identified in our differential expression analysis for C26 and mC26. Blue indicates inhibition and Orange indicates activation of the regulator.